Φορτώνει......
How I manage ibrutinib-refractory chronic lymphocytic leukemia
The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has dramatically changed the management of chronic lymphocytic leukemia (CLL). Although responses have been durable in the majority of patients, relapses do occur, especially in the high-risk patient population. Most relapses o...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345730/ https://ncbi.nlm.nih.gov/pubmed/28096090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-693598 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|